---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088054"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T09:57:14.684160+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics awarded $2M NIH SBIR grant for MT-601 Phase 1 in CAR-relapsed NHL

## Summary
- Awarded $2 million non-dilutive grant from NIH SBIR to support Phase 1 APOLLO study of MT-601 in NHL patients relapsed after anti-CD19 CAR T therapy.
- Grant based on preliminary clinical data (Sept 2023) and non-clinical data (May 2023) showing anti-tumor activity of MT-601.
- Company has now received over $19 million in total non-dilutive funding proceeds.
- APOLLO study evaluates multiTAA-specific T cell product; initial patients showed objective responses with no CRS or ICANS.

## SEC filing metadata
- accession: 0001104659-24-088054
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924088054/0001104659-24-088054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924088054/tm2421372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088054
- JSON: https://secwatch.observer/filing/0001104659-24-088054.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.